Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 2/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | PRKCH | P24723 | 1/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | PTGFR | P43088 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8606477 | 0.82 | ALDH1A1 (0.38) | PRKCA | |
| SCHEMBL3827791 | 0.81 | RAB9A (0.55) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL8947915 | 0.81 | PRKCA (0.38) | RAB9AKDM4ENPC1SMN1; SMN2PRKCA | |
| SCHEMBL8948021 | 0.81 | PRKCA (0.38) | RAB9AKDM4ENPC1SMN1; SMN2PRKCA | |
| SCHEMBL5575172 | 0.78 | RAB9A (0.64) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL14427320 | 0.76 | PTGER1 (0.45) | RAB9AKDM4ENPC1SMN1; SMN2PRKCA | |
| SCHEMBL10734222 | 0.73 | GRIK1 (0.34) | — | |
| SCHEMBL15899754 | 0.72 | FASN (0.35) | SMN1; SMN2 | |
| SCHEMBL11145518 | 0.72 | SLCO2A1 (0.42) | KDM4ESMN1; SMN2PTGFR | |
| SCHEMBL9090304 | 0.71 | MAPT (0.43) | RAB9ANPC1SMN1; SMN2PTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288179-A1 | BIMATOPROST CRYSTALLINE FORM I | FINETECH PHARMACEUTICAL LTD. (IL) | 2011-11-24 | — | — | US | disclosed |
| US-7947740-B2 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD (IL) | 2011-05-24 | — | — | US | disclosed |
| US-20090163596-A1 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD. (IL) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163596-A1 | Bimatoprost crystalline form I | PTGER1, BBC3, CYP2A7 | RAB9A 4172/4885KDM4E 4792/4885NPC1 3989/4885 |
| US-20110288179-A1 | BIMATOPROST CRYSTALLINE FORM I | PTGER1, BBC3, CYP2A7 | RAB9A 4172/4885KDM4E 4792/4885NPC1 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.